Fulcrum Therapeutics Inc logo

Fulcrum Therapeutics Inc

NAS:FULC (USA)  
$ 9.48 +0.33 (+3.61%) 11:09 PM EST
At Loss
P/B:
2.49
Market Cap:
$ 587.14M
Enterprise V:
$ 340.07M
Volume:
424.44K
Avg Vol (2M):
704.25K
Volume:
424.44K
At Loss
Avg Vol (2M):
704.25K

Business Description

Fulcrum Therapeutics Inc logo
Fulcrum Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US3596161097
Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Name Current Vs Industry Vs History
Cash-To-Debt 21.83
Equity-to-Asset 0.91
Debt-to-Equity 0.05
Debt-to-EBITDA -0.1
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 12.63
Distress
Grey
Safe
Beneish M-Score -0.12
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 35.83
9-Day RSI 38.7
14-Day RSI 44.25
6-1 Month Momentum % 121.3
12-1 Month Momentum % 226.28

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.71
Quick Ratio 17.71
Cash Ratio 17.27
Days Sales Outstanding 1.69

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30.4
Shareholder Yield % -19.66

Financials (Next Earnings Date:2024-05-15 Est.)

FULC's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:FULC

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Fulcrum Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2.805
EPS (TTM) ($) -1.58
Beta 3.29
Volatility % 103.83
14-Day RSI 44.25
14-Day ATR ($) 0.758384
20-Day SMA ($) 10.5715
12-1 Month Momentum % 226.28
52-Week Range ($) 2.25 - 13.7
Shares Outstanding (Mil) 61.94

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Fulcrum Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Fulcrum Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Fulcrum Therapeutics Inc Frequently Asked Questions

What is Fulcrum Therapeutics Inc(FULC)'s stock price today?
The current price of FULC is $9.48. The 52 week high of FULC is $13.70 and 52 week low is $2.25.
When is next earnings date of Fulcrum Therapeutics Inc(FULC)?
The next earnings date of Fulcrum Therapeutics Inc(FULC) is 2024-05-15 Est..
Does Fulcrum Therapeutics Inc(FULC) pay dividends? If so, how much?
Fulcrum Therapeutics Inc(FULC) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1